Study Summary
This trial is studying temozolomide and capecitabine to see how well they work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas.
- Intestinal Neuroendocrine Carcinoma
- Pancreatic Neuroendocrine Tumor
- Gastric Neuroendocrine Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
2 Treatment Groups
Arm B (cisplatin, carboplatin, etoposide)
1 of 2
Arm A (capecitabine, temozolomide)
1 of 2
Active Control
Experimental Treatment
126 Total Participants · 2 Treatment Groups
Primary Treatment: Capecitabine · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 34 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To what extent can Capecitabine prove to be harmful for patients?
"Our research team at Power has rated the safety of Capecitabine a 2, as it is only in Phase 2 where there are some findings that back up its security but not yet any evidence for its efficacy." - Anonymous Online Contributor
How many individuals have been recruited to participate in this clinical experiment?
"Affirmative. Clinicaltrials.gov records confirm that this medical trial, which was first published on November 6th 2015, is currently recruiting patients. 126 volunteers must be sourced from 24 distinct clinical sites." - Anonymous Online Contributor
Is this research endeavor still accepting participants?
"Indeed, the details publicized on clinicaltrials.gov attest to this research project still searching for participants. This trial was first posted in November of 2015 and last updated in July of 2022 with a target enrollment number of 126 people at 24 sites." - Anonymous Online Contributor
Have any other experiments utilized Capecitabine for research purposes?
"At present, there are 1745 trials in progress for Capecitabine. 538 of these live studies have reached Phase 3 status. While many clinical sites that host this research can be found in Guangzhou, Guangdong, 83186 different locations worldwide are currently conducting experiments with the medication." - Anonymous Online Contributor
What is the scope of locations where this trial is operational?
"Currently, 24 medical sites are enrolling patients for this trial, including 21st Century Oncology-Fort Apache in Las Vegas, Saint Mary Mercy Hospital in Livonia and University of Cincinnati/Barrett Cancer Center in Cincinnati. There is an additional selection of research centres scattered across the United States." - Anonymous Online Contributor
What clinical applications is Capecitabine most often used to manage?
"Capecitabine is an effective therapy for refractory Ewing sarcoma, Merkel cell cancer, and initial treatment." - Anonymous Online Contributor